http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CO-5700766-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7f82940e47ba7a1188f8e2ffca55e0f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate | 2005-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6cabc765bf3c49b959b63d0a7d996af7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7fec5280d5ae607b17dc9f666dc7a116 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5cd896d02f0a225e704543422bea06d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c31bdd459a9721671bdac1e38eda917d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afabe4132e4fc910f8841120eca5000d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33ef17ce1b98353cf5d735a3907eec57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce4e7516e8f928cbcb8fb73e451e87de |
| publicationDate | 2006-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CO-5700766-A2 |
| titleOfInvention | ANTAGONISTS OF THE A2A RECEIVER OF 2-ALQUINIL-Y 2-ALQUINIL-PIRAZOLO- [4,3-E] -1,2,4 TRIAZOL- [1,5-C] -PIRIMIDINA ADENOSINA |
| abstract | 1. A compound having the structural formula or its pharmaceutically acceptable salt, wherein R is R1, R2, R3, R4 and R5 are independently selected from the group consisting of H, alkyl and alkoxyalkyl; R6 is H, alkyl, hydroxyalkyl or -CH2F; R7, R8 and R9 are independently selected from the group consisting of H, alkoxy alkyl, alkylthio, alkoxyalkyl, halo and -CF3; Z is R10 -aryl, R10-heteroaryl or R10 is 1 to 5 substituents selected independently from the group consisting of hydrogen, alkyl, alkenyl, hydroxy, alkoxy, hydroxyalkyl, hydroxy-alkoxy, alkoxyalkyl, alkoxyalkoxy, alkoxy-alkoxy-alkyl-, (di-alkoxy) -alkyl, (hydroxy) -alkoxyalkyl, R15- cycloalkyl, R15-cycloalkylalkyl, cycloalkyl-oxy, cycloalkyl-O-alkoxy, alkyl-SO2-, alkyl-SO-, halo, -CN, cyanoalkyl, -CHF2, -CF3, -OCHF2, -OCF3, -C (O) R13, -O-alkylene-C (O) OR13, -C (O) Oalkyl, -N (R11) (R12), N (R11) (R12) -alkyl, N (R11) (R12) -alkoxy, - C (O) N (R13) (R16), R11-heteroaryl, R15-h Eterocycloalkyl, R15-heterocycloalkyl-alkyl, R15-heterocycloalkyl-alkoxy, R15-heterocycloalkyl-oxy, CF3-alkylene-O-alkyl, CF3-hydroxyalkyl, (CF3) (hydroxy) alkoxy, cyano-alkoxy, -alkylene-C (O ) O-alkyl, -SO2N (alkyl) 2, (cycloalkyl) hydroxyalkyl, (hydroxyalkyl) alkoxy, (dihydroxy) alkyl, (dihydroxy) alkoxy, -C (= NOR17) -alkyl and -C (= NOR17) -CF3; or two R10 groups in adjacent carbon ring atoms together form -O-CH2-O-, -O- (CH2) 2-O-, ... |
| priorityDate | 2003-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 34.